Icon

ZOMETA (nda021223)- (EQ 4MG BASE/VIAL,EQ 4MG BASE/5ML,EQ 4MG BASE/100ML)

ZOLEDRONIC ACID NOVARTIS
EQ 4MG BASE/VIAL,EQ 4MG BASE/5ML,EQ 4MG BASE/100ML
Yes No
2013-Mar-02 Expired
None None
None No
Zometa is a bisphosphonate indicated for the treatment of: • Hypercalcemia of malignancy • Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.
17 9 13
Total Other Developers None
Drugs with Suitability No
EQ 4MG BASE/VIAL ** ** - - -
EQ 4MG BASE/5ML ** ** - - 5
EQ 4MG BASE/100ML ** ** - - -
NDA Sales Available Total Generic Sales Available
No 10
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ******* *******, ***. *********** ******* *** *****, ***** *****, ***** ******** (**) *****, ****** ****** (***) ***
****** ******* ****** ****** *******, ***. *** *********** **** ******** *****, *******, ******** (**) *****, ****** ****** (***) ***
****** ******* ****** ****** *******, ***. *** *********** **** ******** *****, *******, ******** (**) *****, ****** ****** (***) ***
****** ** ****** **** *** ***** ****** ******* *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ***** ************ ***** ************ (********), *.* *********** ******* *** ** **, */**/**, ******** ******, ****-***, ******** (***) ***
****** **** ****** *** ********* **** ******* **** *********** **************** **, ****, / ****, ******* (***) ***
****** ***** **** *** ***** ************ ******* *********** (***), **** **. ***-*, *********** ****** **** ****, ********** ****, ****** *****, *********, ********* ******, ***** (***) ***
****** *** *** ******* ******* *********** *-**, **, ***, **, **, **, **, ** & *-**, ****, ******* ****** ***** *****, ******, *****, ***** & *** ******, ***** (***) ***
****** ***** ****** *** ***** ****** ******* *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. ***/***-****** / **** **.***/****-*********** , *******-***** ******* , ****** -******, ******, *********, ******* ******, ***** (***) ***
****** *** **** ***** ****** ******* *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-***, **** **: *, ** ** **, ***, ** ** **, ****, *****, ***, ************ *******, ********** ******, **********, ********* ******, ***** (***) ***
****** ****** **** ****** ******** ******* *********** *** *****-** & ***, *-**,**,**, ***** ********** ****, *****, ***, *** ******, ***** (***) ***
****** ***** ****** *** ***** ****** ******* *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.